Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 43Prostatic Neoplasms 41Carcinoma, Non-Small-Cell Lung 36Breast Neoplasms 34Lymphoma 28Leukemia, Myeloid, Acute 25Lymphoma, Non-Hodgkin 21Melanoma 18Colorectal Neoplasms 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Ovarian Neoplasms 15Lung Neoplasms 15Hodgkin Disease 15Hematologic Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Neoplasms 13Neoplasm Metastasis 13Myelodysplastic Syndromes 13Sarcoma 12Leukemia, Lymphocytic, Chronic, B-Cell 12Wilms Tumor 11Head and Neck Neoplasms 11Carcinoma, Renal Cell 11Burkitt Lymphoma 11Triple Negative Breast Neoplasms 10Pancreatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Leukemia 9Glioma 9Fallopian Tube Neoplasms 9

Interventions

Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anal Canal Carcinoma × 30 days × Clear all
NCT02314169 2026-05-28

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
143 enrolled 16 charts
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡